Braeburn Drug Patent Portfolio
Braeburn owns 1 orange book drug protected by 9 US patents Given below is the list of Braeburn's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10912772 | Opioid formulations | 26 Jul, 2032 | Active |
| US11110084 | Opioid formulations | 26 Jul, 2032 | Active |
| US11135215 | Opioid formulations | 26 Jul, 2032 | Active |
| US12161640 | Opioid formulations | 26 Jul, 2032 | Active |
| US12318379 | Opioid Formulations | 26 Jul, 2032 | Active |
| US9937164 | Opioid formulations | 26 Jul, 2032 | Active |
| US8236292 | Liquid depot formulations | 10 Jan, 2027 | Active |
| US8236755 | Opioid depot formulations | 31 Jul, 2026 | Active |
| US8545832 | Lipid depot formulations | 06 Jun, 2025 | Expired |
Latest Legal Activities on Braeburn's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Braeburn.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 10 Jun, 2025 | US12318379 |
| Patent eGrant Notification | 03 Jun, 2025 | US12318379 |
| Email Notification | 03 Jun, 2025 | US12318379 |
| Recordation of Patent eGrant | 03 Jun, 2025 | US12318379 |
| Mail Patent eGrant Notification | 03 Jun, 2025 | US12318379 |
| Patent Issue Date Used in PTA Calculation | 03 Jun, 2025 | US12318379 |
| Email Notification | 22 May, 2025 | US12318379 |
| Issue Notification Mailed | 21 May, 2025 | US12318379 |
| Application Is Considered Ready for Issue | 13 May, 2025 | US12318379 |
| Dispatch to FDC | 13 May, 2025 | US12318379 |
| Mailing Corrected Notice of Allowability | 05 May, 2025 | US12318379 |
| Email Notification | 05 May, 2025 | US12318379 |
| Corrected Notice of Allowability | 01 May, 2025 | US12318379 |
| Pubs Case Remand to TC | 29 Apr, 2025 | US12318379 |
| Amendment after Notice of Allowance (Rule 312) | 25 Apr, 2025 | US12318379 |
Braeburn's Family Patents
Braeburn Drug List
Given below is the complete list of Braeburn's drugs and the patents protecting them.
1. Brixadi
Brixadi is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10912772 | Opioid formulations |
26 Jul, 2032
(6 years from now)
| Active |
| US11110084 | Opioid formulations |
26 Jul, 2032
(6 years from now)
| Active |
| US11135215 | Opioid formulations |
26 Jul, 2032
(6 years from now)
| Active |
| US12161640 | Opioid formulations |
26 Jul, 2032
(6 years from now)
| Active |
| US12318379 | Opioid Formulations |
26 Jul, 2032
(6 years from now)
| Active |
| US9937164 | Opioid formulations |
26 Jul, 2032
(6 years from now)
| Active |
| US8236292 | Liquid depot formulations |
10 Jan, 2027
(9 months from now)
| Active |
| US8236755 | Opioid depot formulations |
31 Jul, 2026
(4 months from now)
| Active |
| US8545832 | Lipid depot formulations |
06 Jun, 2025
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brixadi's drug page